Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di fase iniziale su Venetoclax, lenalidomide e rituximab/ialuronidasi nei linfomi a crescita lenta che si sono ripresentati dopo il trattamento o che non hanno risposto al trattamento

29 settembre 2026 aggiornato da: Thomas Jefferson University

Uno studio di fase I su Venetoclax + Lenalidomide + Rituximab ialuronidasi nel linfoma non-Hodgkin indolente (iNHL) recidivato o refrattario (R/R).

This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back after treatment (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking the action of a protein called Bcl-2, that helps cancer cells survive. Immunotherapy with lenalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as rituximab and rituximab hyaluronidase, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this research is to determine if the combination of three drugs, venetoclax, lenalidomide, and rituximab hyaluronidase are safe to administer in patients whose low-grade lymphoma (follicular or marginal zone) has come back after initial therapy or was not responsive to initial therapy.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To determine the safety (and the recommended phase 2 dose [RP2D]), of the combination of venetoclax, lenalidomide, and rituximab hyaluronidase in patients with relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL).

SECONDARY OBJECTIVES:

I. To determine the overall response rate (ORR) with rituximab hyaluronidase, venetoclax, and lenalidomide.

II. To determine the 2-year progression-free survival (PFS) with rituximab hyaluronidase, venetoclax, and lenalidomide.

III. To determine the overall survival (OS) following therapy with rituximab hyaluronidase, venetoclax, and lenalidomide.

CORRELATIVE STUDY OBJECTIVES:

I. Describe changes in the level of expression and expression ratio between anti-apoptotic and pro-apoptotic BCL-2 family members before and after therapy with venetoclax/lenalidomide/rituximab hyaluronidase for each patient.

II. Examine the metabolic landscape before and after venetoclax/lenalidomide/rituximab hyaluronidase and their effects on mitochondrial metabolism.

III. Describe the immune effects of venetoclax and its effects on serum cytokines and different immune cell subsets (e.g. B-cells, T-cells, dendritic cells, etc.) in addition to T-cell activation markers and expression of immune checkpoint proteins.

OUTLINE: This is a dose-escalation study of venetoclax.

Patient receive venetoclax orally (PO) once daily (QD) on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab intravenously (IV) on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) subcutaneously (SC) on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, and then for up to 5 years.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

4

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Sidney Kimmel Cancer Center at Thomas Jefferson University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Signed informed consent form

  • Ability and willingness to comply with the requirements of the study protocol

  • Able to swallow oral medications whole

  • Patients must have received at least one prior systemic therapy

  • Histologically confirmed indolent B-cell non-Hodgkin's lymphoma (NHL) of any of the following subtypes recognized by the World Health Organization (WHO) classification: Follicular lymphoma and marginal zone lymphoma. Patients with indolent non-Hodgkin's Lymphoma (iNHL) should have received at least 1 previous prior therapy

  • Patients must have an indication for treatment by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria in the opinion of the investigator

  • Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size

  • All study participants must be registered into the mandatory lenalidomide risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program

  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS program

  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent. Inability to take any form of prophylaxis excludes participation

  • Eastern Cooperative Oncology Group performance status of 0, 1, or 2

  • Hemoglobin >= 9 g/dL (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)

  • Absolute neutrophil count >= 1.0 x 10^9/L (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)

  • Platelet count >= 75 x 10^9/L (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)

  • International normalized ratio > 1.5 x upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation

  • Partial thromboplastin time (PTT) or activated PTT (aPTT) =< 1.5 x ULN

  • Creatinine clearance >= 60 mL/min, calculated with the use of the 24-hour creatinine clearance or modified Cockcroft-Gault equation

  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN

  • Total bilirubin =< 1.5 x ULN (or =< 3 x ULN for patients with documented Gilbert syndrome)

  • Women of childbearing potential must have a negative serum or urine pregnancy test result within 14 days prior to registration

  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax and lenalidomide or 12 months after the last dose of rituximab, whichever is longer * Women must refrain from donating eggs during this same period

    * A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) * Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception

  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: * With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab and for at least 30 days after the last dose of venetoclax and lenalidomide whichever is longer. Men must refrain from donating sperm during this same period * With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception

Exclusion Criteria:

Known hypersensitivity to any of the study drugs study drugs

  • Known central nervous system (CNS) involvement by lymphoma
  • Prior allogeneic stem cell transplant is not permitted if patient is fewer than 4 months from transplant and has either active graft versus host disease or on immunosuppression
  • History of severe allergic reactions to humanized monoclonal antibodies
  • Prior use of lenalidomide or venetoclax or other BCL2 family inhibitors; prior rituximab is allowed as long as they continue to express CD20 and are not rituximab refractory as defined as: * Did not respond (at least a partial response [PR]) to rituximab or rituximab (R)-chemoregimen therapy * Time to disease progression < 6 months after last rituximab dose
  • History of other malignancy that could affect compliance with the protocol or interpretation of results * Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible * Patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded. Individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to registration
  • Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)
  • Received the following agents within 7 days prior to registration: * Steroid therapy for anti-neoplastic intent * Strong and moderate CYP3A inhibitors * Strong and moderate CYP3A inducers * Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody * Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation * Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV deoxyribonucleic acid (DNA) is undetectable. These patients must be willing to undergo monthly DNA testing.
  • Known infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1)
  • Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
  • Pregnant or lactating, or intending to become pregnant during the study
  • Recent major surgery (within 6 weeks prior to the start of cycle 1, day 1) other than for diagnosis
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • Known allergy to both xanthine oxidase inhibitors and rasburicase

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)

Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Given PO

Altri nomi:
  • CC-5013
  • Revimid
  • CC5013
  • 191732-72-6,
  • 3-(4-ammino-1-osso-1,3-diidro-2H-isoindol-2-il)piperidina-2,6-dione,
  • 703813,
  • CDC 501,
  • lenalidomide,

Given IV

Altri nomi:
  • IDEC-C2B8
  • 174722-31-7,
  • 687451,
  • ABP 798,
  • BI 695500,
  • Anticorpo monoclonale C2B8,
  • Anticorpo chimerico anti-CD20,
  • CT-P10,
  • IDEC-102,
  • Anticorpo monoclonale IDEC-C2B8,
  • MabThera,
  • PF-05280586,
  • Rituxan,
  • Rituximab,
  • RITUX

Given PO

Altri nomi:
  • ABT-199,
  • 4-(4-((2-(4-clorofenil)-4
  • 1257044-40-8,
  • 4-dimetilcicloes-1-en-1-il)metil)piperazin-1-il)-N-((3-nitro-4-((tetraidro-2H-piran-4-ilmetil)ammino)fenil)solfonil)- 2-(1H-pirrolo(2,3-b)piridin-5-ilossi)benzammide,
  • ABT-0199,
  • ABT199,
  • RG7601,
  • GDC-0199,

Given SC

Altri nomi:
  • Rituximab/ialuronidasi umana
  • Rituxan Hycela,
  • Rituximab più ialuronidasi,
  • Rituximab/ialuronidasi,

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of dose-limiting toxicities
Lasso di tempo: During the first 56 days of therapy

Toxicity incidences assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, will be tabulated by patient cohort.

During the first 56 days of therapy

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response rate
Lasso di tempo: At the end of 12 month treatment period

Defined as the sum of the proportions of patients achieving a complete (CR) or partial response (PR) according to the Lugano Response Criteria. Analyses of efficacy outcomes will be descriptive. A 90% confidence interval will be computed for the best response rate (CR+PR rate) during the 12 month treatment period.

At the end of 12 month treatment period
Progression-free survival (PFS)
Lasso di tempo: Time from study registration to documented disease progression or death from any cause, assessed at 2 years

PFS distributions will be estimated using the Kaplan-Meier method, and the median PFS along with its corresponding 95% confidence interval will be reported.

Time from study registration to documented disease progression or death from any cause, assessed at 2 years
Overall survival (OS)
Lasso di tempo: Time from study registration to death from any cause, assessed at 2 years

OS distributions will be estimated using the Kaplan-Meier method, and the median OS along with its corresponding 95% confidence interval will be reported.

Time from study registration to death from any cause, assessed at 2 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Livello di espressione e rapporto di espressione tra proteine ​​​​della famiglia BCL-2 anti-apoptotiche e pro-apoptotiche misurate mediante citometria a flusso e acido ribonucleico messaggero (mRNA)
Lasso di tempo: 42 giorni dall'inizio del trattamento fino alla fine del trattamento
42 giorni dall'inizio del trattamento fino alla fine del trattamento
Metabolic landscape
Lasso di tempo: 42 days of screening through until end of treatment

Adenosine triphosphate (ATP) will be measured by mass spectroscopy and metabolic proteins will described by immunohistochemistry.

42 days of screening through until end of treatment
Immune profile
Lasso di tempo: 42 days of starting treatment through until end of treatment

Flow cytometry will be used to measure T-cell and B-cell subsetswill be used to quantitate PD-1/PD-L1.

42 days of starting treatment through until end of treatment
Immune profile
Lasso di tempo: 42 days of starting treatment through until end of treatment

Immunohistochemistry will be used to quantitate PD-1/PD-L1.

42 days of starting treatment through until end of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Ubaldo R Martinez-Outschoorn, MD, Thomas Jefferson University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 ottobre 2020

Completamento primario (Effettivo)

16 maggio 2024

Completamento dello studio (Stimato)

1 marzo 2027

Date di iscrizione allo studio

Primo inviato

9 aprile 2020

Primo inviato che soddisfa i criteri di controllo qualità

23 giugno 2020

Primo Inserito (Effettivo)

25 giugno 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi